Treatment-Resistant Depression in New York: What It Means and What Options Exist

Being told that your depression is "treatment-resistant" can feel like being handed a label with no solution attached. For many people, it comes after years of trying medications, adjusting doses, switching therapists, and still not feeling better. It can erode hope in a way that the depression itself sometimes doesn't.

But treatment-resistant depression is not a dead end. It is a clinical designation that points toward a different — and more targeted — set of treatment strategies. Understanding what it means, why it happens, and what options exist is an important first step.

What "Treatment-Resistant" Actually Means

Treatment-resistant depression (TRD) is generally defined as major depressive disorder that has not adequately responded to at least two antidepressant trials, each conducted at an adequate dose and for an adequate duration — typically at least six to eight weeks.

Two important clarifications:

First, "not responding" means the symptoms haven't improved sufficiently — not that they haven't changed at all. Partial improvement that leaves significant symptoms in place still qualifies as inadequate response.

Second, the adequacy of prior trials matters. Many people have technically "tried" medications that were underdosed, discontinued too soon, or switched before they had a real chance to work. A thorough psychiatric reassessment will often review whether prior trials were genuinely adequate before concluding that TRD is the right diagnosis.

Estimates suggest that roughly 30% of people treated for depression do not achieve full remission with first- or second-line antidepressants. TRD is not rare — it's just underrecognized and undertreated.

Why Depression Sometimes Doesn't Respond to Standard Treatment

There is no single explanation for treatment resistance. In practice, multiple factors may contribute:

Pharmacogenomic differences — Genetic variation affects how individuals metabolize psychiatric medications. Some people are rapid metabolizers who clear medications too quickly to achieve therapeutic levels; others are poor metabolizers who accumulate drugs at higher-than-expected concentrations. Pharmacogenomic testing can help identify these patterns.

Diagnostic complexity — Some cases of apparent TRD involve an incomplete or inaccurate initial diagnosis. Unrecognized bipolar spectrum disorder, ADHD, PTSD, or personality pathology can all present with depressive symptoms while requiring different treatment approaches than standard MDD.

Undertreated comorbidities — Anxiety disorders, chronic insomnia, alcohol or substance use, and chronic pain can all sustain or worsen depression. Treating depression without addressing co-occurring conditions limits outcomes.

Prior inadequate trials — As noted above, medications that were tried at insufficient doses or durations may not represent genuine therapeutic failures.

Biological subtype — Depression is not one disease. Subtypes differ in their neurobiology, and the glutamatergic, inflammatory, and HPA-axis pathways implicated in some forms of depression may not be well-addressed by serotonergic medications.

What a Reassessment Should Include

If you believe you may have treatment-resistant depression, the most valuable first step is a thorough reassessment — not just a new prescription. A meaningful reassessment should include:

• A complete review of all prior medication trials, doses, and durations

• Screening for co-occurring diagnoses that may be driving or sustaining symptoms

• Review of sleep, substance use, medical conditions, and lifestyle factors

• A fresh diagnostic formulation, not just continuation of prior assumptions

• An open conversation about what options exist beyond what's been tried

  
  

Treatment Options for TRD in New York

Spravato® (esketamine) — FDA-approved specifically for treatment-resistant depression, esketamine works on the glutamate system — a different neurotransmitter pathway from standard antidepressants. It is administered as a nasal spray in a certified clinical setting under direct supervision. Clinical trials demonstrated meaningful reductions in depression severity for TRD patients who had not responded to multiple prior treatments. Onset of effect can occur within hours to days, unlike the weeks required by oral antidepressants.

Medication optimization — This may involve switching to a different antidepressant class, combining agents, or augmenting with medications like lithium, atypical antipsychotics, or thyroid supplementation that can enhance antidepressant response.

Evidence-based psychotherapy — CBT, DBT, and other structured approaches remain important components of treatment, particularly when combined with medication adjustment.

Collaborative second opinions — Working with a psychiatrist who has specific experience managing treatment-resistant cases — and who approaches the diagnostic picture fresh — can identify angles that prior providers missed.

Living With TRD While Pursuing Treatment

One of the hardest aspects of treatment-resistant depression is the toll that the search for effective treatment takes on its own. Each unsuccessful trial can deepen hopelessness and erode motivation to keep trying.

This is a real and clinically recognized phenomenon. It is also not a reason to stop. It is a reason to make sure that any further treatment attempts are pursued with a clear strategy, realistic expectations, and active communication with your provider about what you're experiencing.

Progress in TRD is often incremental — partial improvement, followed by adjustments, followed by further improvement. It rarely follows the linear path that first-episode depression sometimes does.

Finding TRD Care in New York

Not all psychiatric practices in New York are equipped to manage treatment-resistant cases. Look for a practice with experience in complex presentations, access to advanced treatment options, and a willingness to do the thorough reassessment that TRD requires.

If you've spent months or years cycling through medications that haven't worked, the answer isn't more patience — it's a better strategy. At Aurora Wellness, we specialize in exactly that: comprehensive reassessment, advanced treatment options including Spravato®, and psychiatric care that doesn't give up when the first few approaches fall short. Our Brooklyn and White Plains locations offer in-person Spravato® treatment, and telehealth psychiatric services are available throughout New York State. If what you've tried hasn't been enough, we're built for that.